AbbVie on Twitter
Looking for more news from AbbVie? Follow us on social media.
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
April 07, 2021- Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo[1]
-
April 07, 2021-- Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine to be presented at the Clinical Trials Plenary Session; study was also only headache topic to earn Merit of Distinction in 2021
-
April 01, 2021Revolutionary, Clinically Proven Product Addresses Multi-Factorial Causes & Symptoms of Neck Aging
-
April 01, 2021- In SELECT-PsA 1, RINVOQ™ (upadacitinib, 15 mg and 30 mg) improved key joint and skin symptoms up to 24 weeks, including enthesitis[1]
-
March 31, 2021
-
March 30, 2021- If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine[1]
-
March 17, 2021- National scholarship awards $3,000 to 40 exceptional students living with cystic fibrosis (CF) for academic excellence, creativity and community involvement
-
February 25, 2021- If approved, this is expected to be the first eye drop to treat presbyopia
-
February 24, 2021- HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis[1]
-
February 23, 2021- In Today's Increasingly Digital World, Over-The-Counter REFRESH® DIGITAL Lubricant Eye Drops Bring Temporary Relief to Dry, Irritated Eyes
-
February 22, 2021- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p<0.001)[1]
-
February 19, 2021
-
February 18, 2021
-
February 10, 2021- Collaboration leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders
-
February 10, 2021-- Children living with neurogenic detrusor overactivity who are not adequately managed with anticholinergic medication now have a new treatment option prior to surgical intervention
-
February 03, 2021- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56
-
January 26, 2021NEW TECHNOLOGY ALLOWS FOR THE TREATMENT OF TWO AREAS OF FAT AT ONCE AND NEW ELITE APPLICATORS DESIGNED FOR IMPROVED FIT AND COMFORT
-
January 25, 2021- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2]
-
January 15, 2021- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications
-
January 12, 2021-- Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts --
-
January 07, 2021- A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab (600 mg or 1200 mg) achieved both primary endpoints, demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo[1,2]
-
January 05, 2021- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo (p<0.001)[1]
-
December 23, 2020- Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM
-
December 11, 2020- Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoid arthritis (RA)[1-4]
-
December 10, 2020- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1]
-
December 09, 2020- Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe ulcerative colitis[1]
-
December 05, 2020- New five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab compared to 17.0 months in patients taking bendamustine plus rituximab (BR) after three years or more off treatment[1]
-
December 02, 2020- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases
-
December 01, 2020
-
November 16, 2020NUMBER 1 SELLING PRODUCT OF ITS KIND CELEBRATES BOTH LOYAL AND NEW CONSUMERS WITH EXCLUSIVE OFFER ON NOVEMBER 18th
-
November 12, 2020
-
November 05, 2020- Nearly 40 abstracts on eight investigational and approved products across 11 cancer types to be presented
-
October 30, 2020- Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis; Adjusted Diluted EPS of $2.83
-
October 29, 2020-- New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis[1]
-
October 28, 2020- Researchers to share updates on long-term safety and efficacy of RINVOQ for the treatment of moderate to severe rheumatoid arthritis
-
October 28, 2020- Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly four out of 10 people in the U.S.
-
October 19, 2020- In three pivotal Phase 3 studies, RINVOQ met co-primary and all secondary endpoints in adult and adolescent patients with moderate to severe atopic dermatitis[1-3]
-
October 19, 2020
-
October 16, 2020- The FDA approval of VENCLEXTA for newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a series of trials including two Phase 3 trials - VIALE-A (M15-656) and VIALE-C (M16-043)
-
October 08, 2020- My Glaucoma, My Design calls on people to share their stories and photos of how they manage their glaucoma
-
October 07, 2020-- Acquisition Immediately Enhances Allergan Aesthetics' Leading International Dermal Filler Portfolio & Pipeline --
-
October 06, 2020
-
October 02, 2020- New data from Phase 3 ADVANCE trial evaluating investigational medicine atogepant for the preventive treatment of migraine accepted for oral presentation
-
September 30, 2020In-Office Skin-Resurfacing Treatment Provides Transformative, Age-Defying Results
-
September 28, 2020- Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury
-
September 16, 2020- Forty students received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvement/extracurricular activities
September 16, 2020Partnership will educate on body contouring options and encourage consumers to "Shape Your Moment" with CoolSculpting®-
September 11, 2020- Final data from the 12-week DYSCOVER study, the first randomized trial of DUODOPA® (levodopa/carbidopa intestinal gel) on the duration and severity of dyskinesia in patients with advanced Parkinson's disease
-
September 11, 2020
-
September 04, 2020AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)
-
September 03, 2020
-
August 31, 2020- Each Monday throughout Pain Awareness Month (September), online influencers share motivations for finding a headache specialist to discuss treatment options
-
August 25, 2020- RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1]
-
August 12, 2020- Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are ineligible for chemotherapy
-
July 31, 2020- On May 8, 2020, AbbVie Completed its Acquisition of Allergan, Significantly Expanding and Diversifying AbbVie's Revenue Base with New Therapeutic Areas, Enhancing Long-Term Growth Potential, and Enabling Investment in Innovation for each of its Therapeutic Categories
-
July 29, 2020- Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period
-
July 28, 2020- Positive top-line results show upadacitinib (15 mg and 30 mg) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in adult and adolescent patients with moderate to severe atopic dermatitis versus placebo plus TCS[1]
-
July 21, 2020- Upadacitinib (15 mg and 30 mg) monotherapy showed significant improvement in skin clearance and reduction in itch at week 16 in adult and adolescent patients with moderate to severe atopic dermatitis versus placebo[1]
-
July 09, 2020- Updated Label Now Includes Pediatric Patients with Lower Limb Spasticity Caused by Cerebral Palsy
-
June 23, 2020- Submission is based on results of more than five years of follow-up data from the Phase 3 iNNOVATE clinical trial evaluating IMBRUVICA in combination with rituximab for patients with WM. This is the longest follow-up data available for a BTK inhibitor in WM
-
June 22, 2020- Application Seeks to Extend Use of BOTOX® for Patients 5 to 17 Years Old
-
June 18, 2020- Top-line results from a Phase 3 study evaluating RINVOQ in moderate to severe atopic dermatitis in adults and adolescents show both doses of upadacitinib (15 mg and 30 mg) monotherapy met all primary and secondary endpoints versus placebo[1]
-
June 17, 2020
-
June 15, 2020JUVÉDERM® VOLUMA™ XC IS FIRST AND ONLY PRODUCT OF ITS KIND APPROVED BY THE FDA FOR USE IN THE CHIN
-
June 15, 2020- Real-world studies assessed persistence of BOTOX® (onabotulinumtoxinA) versus calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)
-
June 13, 2020- Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo
-
June 12, 2020- New head-to-head data from the IMMerge Phase 3b open-label study show SKYRIZI demonstrated superiority to COSENTYX at week 52, with 66 percent of SKYRIZI patients achieving completely clear skin (PASI 100) versus 40 percent of COSENTYX patients[1]
-
June 10, 2020- Data show the clinical activity of ABBV-3373 and support advancing the development of the platform in rheumatoid arthritis and initiating clinical studies in other immune-mediated diseases[1]
-
June 10, 2020- AbbVie and Genmab entered into a broad collaboration to jointly develop and commercialize three of Genmab's next-generation bispecific antibody products, including epcoritamab
-
June 06, 2020- In SELECT-CHOICE, RINVOQ™ (upadacitinib, 15 mg, once daily) met both the primary (non-inferiority) and key secondary (superiority) endpoints compared to ORENCIA® (abatacept) on change from baseline in DAS28-CRP at week 12 in patients with rheumatoid arthritis and inadequate response to biologic DMARDs[1]
-
June 04, 2020- Long-term results from the SELECT-COMPARE and SELECT-MONOTHERAPY studies showed that RINVOQ™ (upadacitinib, 15 mg) continued to improve signs and symptoms in patients with rheumatoid arthritis through 72 and 84 weeks, respectively[1,2]
-
June 01, 2020- Submissions supported by two Phase 3 studies in which RINVOQ demonstrated improved joint outcomes, physical function and skin symptoms, with a greater proportion of patients achieving minimal disease activity versus placebo* [1,2]
-
June 01, 2020Connecting with patients to participate in device tracking enables them to be contacted in the event of a safety issue
-
May 29, 2020- Uterine fibroids are the most common type of benign tumor in women of reproductive age[1]
-
May 27, 2020- First presentation of the SELECT-CHOICE study evaluating efficacy and safety of RINVOQ™ (upadacitinib) compared to abatacept in patients with moderate to severe active rheumatoid arthritis
Our history
 |
Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more
Societal impact
 |
Our commitment to science is a commitment to better our society. Read our 2021 ESG report
Ratings and recognition
 |
We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more
Annual report
 |
See our latest 2022 Annual Report on Form 10-K. Learn more
